89bio (NASDAQ: ETNB), a clinical-stage biopharmaceutical company specializing in liver and cardiometabolic disease therapies, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The company's management will engage in a fireside chat on June 11, 2025, at 11:20 AM EDT, along with one-on-one investor meetings. The presentation will be available via webcast through 89bio's investor relations website, with replay access for approximately 30 days after the event.
89bio (NASDAQ: ETNB), un'azienda biofarmaceutica in fase clinica specializzata in terapie per malattie epatiche e cardiometaboliche, ha annunciato la sua partecipazione alla 46ª Conferenza Globale Annuale sulla Sanità di Goldman Sachs. Il management dell'azienda parteciperà a una discussione informale il 11 giugno 2025 alle 11:20 EDT, oltre a incontri individuali con investitori. La presentazione sarà disponibile in webcast tramite il sito web delle relazioni con gli investitori di 89bio, con accesso alla replica per circa 30 giorni dopo l'evento.
89bio (NASDAQ: ETNB), una empresa biofarmacéutica en etapa clínica especializada en terapias para enfermedades hepáticas y cardiometabólicas, ha anunciado su participación en la 46ª Conferencia Global Anual de Salud de Goldman Sachs. La dirección de la empresa participará en una charla informal el 11 de junio de 2025 a las 11:20 AM EDT, junto con reuniones individuales con inversores. La presentación estará disponible en webcast a través del sitio web de relaciones con inversores de 89bio, con acceso a la repetición durante aproximadamente 30 días después del evento.
임상 단계의 생명공학 회사인 89bio(NASDAQ: ETNB)는 간 및 심장대사 질환 치료제에 특화된 기업으로, 골드만 삭스 제46회 연례 글로벌 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. 회사 경영진은 2025년 6월 11일 오전 11시 20분(EDT)에 파이어사이드 챗에 참여하며, 1:1 투자자 미팅도 진행할 예정입니다. 발표는 89bio 투자자 관계 웹사이트를 통해 웹캐스트로 제공되며, 행사 종료 후 약 30일간 다시보기 서비스를 이용할 수 있습니다.
89bio (NASDAQ : ETNB), une société biopharmaceutique en phase clinique spécialisée dans les thérapies des maladies hépatiques et cardiométaboliques, a annoncé sa participation à la 46e Conférence mondiale annuelle sur la santé de Goldman Sachs. La direction de l'entreprise participera à une discussion informelle le 11 juin 2025 à 11h20 EDT, ainsi qu'à des réunions individuelles avec des investisseurs. La présentation sera disponible en webcast via le site des relations investisseurs de 89bio, avec un accès en replay pendant environ 30 jours après l'événement.
89bio (NASDAQ: ETNB), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf Therapien für Leber- und kardiometabolische Erkrankungen spezialisiert hat, hat seine Teilnahme an der 46. jährlichen globalen Gesundheitskonferenz von Goldman Sachs angekündigt. Das Management des Unternehmens wird am 11. Juni 2025 um 11:20 Uhr EDT an einem Fireside-Chat teilnehmen sowie Einzelgespräche mit Investoren führen. Die Präsentation wird per Webcast über die Investor-Relations-Website von 89bio verfügbar sein, mit einer Wiedergabemöglichkeit für etwa 30 Tage nach der Veranstaltung.
Positive
None.
Negative
None.
SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025 at 11:20 AM EDT and participate in one-on-one investor meetings.
The webcast of the fireside chats will be accessible in the investor section of 89bio’s website. A replay of the webcasts will be available for approximately 30 days following each conference.
About 89bio 89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through Phase 3 clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
